Magnus Ingelman-Sundberg

Employment Information:

1996-Present	Professor of Molecular Toxicology; Karolinska Institute – Department of Physiology and Pharmacology
2006-Present	Section Head of Pharmacogenetics; Karolinska Institute – Department of Physiology and Pharmacology
1987-1996	Acting Professor of Physiological Chemistry; Karolinska Institute – Department of Medical Biochemistry and Biophysics
1977-1987	Lecturer in Physiological Chemistry; Karolinska Institute – Department of Medical Biochemistry and Biophysics
1976-1977	Research Assistant in Physiological Chemistry; Karolinska Institute – Department of Medical Biochemistry and Biophysics

Education:

1978	BSc. Med (med kand), Karolinska Institutet
1977	Docent in Physiological Chemistry
1977	PhD in Physiological Chemistry
1975	Civil Engineer, Royal Institute of Technology, Stockholm

Academic awards and distinctions:

2017-2022	ERC Advanced Grant
2008-2018	Member of the Nobel Assembly at Karolinska Institutet
2018	BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology
2014-2016	Ranked as the one of the world's most cited authors within the category Pharmacology (http://isihighlycited.com/)
2014	Categorized by Thomson Reuters as one of the world's most influential scientific minds (http://sciencewatch.com/sites/sw/files/sw-article/media/worlds-most-influential-scientific-minds-2014.pdf)
2011	The John G Warner Pfizer Lectureship in Pharmaceutical Sciences, University of Michigan, USA
2008	The Bengt Danielsson Prize, The Swedish Academy of Pharmaceutical Sciences
2003	The ISSX European Scientific Achievement Award

1996	The Gerhard B Zbinden Lecture Award, EUROTOX
1990	Honorary member of The American Society for Biochemistry and Molecular Biology
1989	The Svedberg Price, The Swedish Society for Biochemistry and Molecular Biology

Teaching awards:

2000	The Karolinska Institutet Pedagogical Award
1978	Mäster from The Student Union at Karolinska Institutet

Main supervisor to a PhD degree for 32 postgraduate students, postdoctoral training for 32 PhDs. The research group ranked as outstanding in Karolinska Institutet's External Research Assessment (ERA) in 2010.

Activities within wider Academic Community:

More than 490 original papers, 31 024 citations (45 519 in Google Scholar), and an h-factor of 91 (ISI) or 117 (Google Scholar).

Member of Editorial Advisory Boards of e.g. *Trends in Pharmacological Sciences*, *Pharmacogenetics and Genomics*, *Pharmacogenomics*, *Drug Metabolism Reviews*, *Drug Metabolism and Disposition*.

Chairman of the Microsomes and Drug Oxidation International Advisory Committee, mdo.ki.se.

Selected publications

van der Lee M, Allard WG, Vossen RHAM, Baak-Pablo RF, Menafra R, Deiman BALM, Deenen MJ, Neven P, Johansson I, Gastaldello S, **Ingelman-Sundberg M**, Guchelaar HJ, Swen JJ, Anvar SY. Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. *Sci Transl Med*. 2021 Jul 21;13(603):eabf3637.

Jukić MM, Smith RL, Molden E, **Ingelman-Sundberg M**. Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. *Clin Pharmacol Ther*. 2021 Mar 31. doi: 10.1002/cpt.2246.

Riede J, Wollmann BM, Molden E, **Ingelman-Sundberg M**. Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low clearance. *Drug Metab Dispos*. 2021 Jun 1:DMD-AR-2020-000340.

Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, **Ingelman-Sundberg M**, Leucht S, Jukic MM. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2021 Mar 1;78(3):270-280.

Oliva-Vilarnau N, Vorrink SU, **Ingelman-Sundberg M**, Lauschke VM. A 3D Cell Culture Model Identifies Wnt/β-Catenin Mediated Inhibition of p53 as a Critical Step during Human Hepatocyte Regeneration. *Adv Sci (Weinh)* 2020 Aug;7(15):2000248.

Hurrell T, Kastrinou-Lampou V, Fardellas A, Hendriks DFG, Nordling Å, Johansson I, Baze A, Parmentier C, Richert L, **Ingelman-Sundberg M**. Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. *Cells.* 2020 Apr 14;9(4):964.

Jukic MM, Smith RL, Haslemo T, Molden E, **Ingelman-Sundberg M**. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. *Lancet Psychiatry* 2019 May;6(5):418-426.

Lauschke VM, Barragan I, **Ingelman-Sundberg M**. Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities. *Annu. Rev. Pharmacol. Toxicol.* 2018 01;58():161-185

Lauschke VM, Vorrink SU, Moro SM, Rezayee F, Nordling Å, Hendriks DF, Bell CC, Sison-Young R, Park BK, Goldring CE, Ellis E, Johansson I, Mkrtchian S, Andersson TB, **Ingelman-Sundberg M**. Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. *Hepatology* 2016 11;64(5):1743-1756.

Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J.* 2005;5(1):6-13. doi: 10.1038/sj.tpj.6500285.